Skip to main contentSkip to navigationSkip to search

Curasight to present at HC Andersen Capital

November 23, 2022


Copenhagen, Denmark, 23 November 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q3 2022 at HC Andersen Capital, 28 November 2022.

The presentation will include an update on the momentum and business progress made by the company during first three quarters of 2022 and look ahead at the coming news flow expected in rest of the year. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer as well as Neuroendocrine and head & neck cancer.

The presentation will be webcasted live 12:00 - 12:30 (CET), Monday 28 November 2022.

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight’s website, after the presentation is completed.

For more information please click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.